A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
Astellas Pharma Inc
National Cancer Institute, Naples
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
M.D. Anderson Cancer Center
Engeneic Pty Limited
OHSU Knight Cancer Institute
University Health Network, Toronto
BeiGene
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OHSU Knight Cancer Institute
Fudan University
Aravive, Inc.
National Cancer Institute (NCI)
Shanghai Henlius Biotech
OncoSec Medical Incorporated
Fudan University
NextCure, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco